The authors report on three elderly patients treated with escitalopram, 10 mg/day, who presented with marked sinus bradycardia. The bradycardia was clinically symptomatic or asymptomatic and disappeared within 24 hours after escitalopram was discontinued. Clinicians should be cautious about cardiac effects when using a selective serotonin reuptake inhibitor in elderly people, even at a low dose.
INTRODUCTION
Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed for the treatment of depression, anxiety disorders, and many other psychiatric and chronic disorders. During the last 10 years, there has been an increase in the use of escitalopram as well as an associated increase in overdoses. One advantage of this antidepressant group is that it appears to be relatively safe in terms of side effects and overdoses compared with older tricyclic antidepressants, especially in elderly individuals 1 . The majority of SSRI overdoses cause minor effects characterized by mild to moderate serotonin toxicity, although occasionally, large overdoses cause seizures 2 . There are few published reports of the effects of escitalopram overdose. However, cardiac QT-interval prolongation and bradycardia have been reported, mainly with citalopram and, more recently, in case reports of escitalopram toxicity [2] [3] [4] [5] [6] [7] [8] [9] [10] . This case series report suggests that escitalopram may induce bradycardia in some elderly patients.
CASE REPORTS Patient 1:
A 65-year-old man without any significant medical history was admitted to the emergency room because of sudden-onset vomiting, vertigo, dysarthria, ataxia, and weakness of his left side. Neurological examination revealed left facial palsy, dysarthria, absence of gag reflex, and left pharyngeal arch elevation and hemiparesis. Family history was positive for stroke on the maternal side and for heart disease on the paternal side. He had been taking only escitalopram, 10 mg/day, for 10 days to treat depression. Electrocardiography (ECG) at admission was abnormal, demonstrating bradycardia (30-40 beats per min (bpm)) and QT prolongation. Diffusion-weighted magnetic resonance imaging (MRI) confirmed an acute ischemic lacunar infarction of the left pons. Doppler ultrasonography and cerebral MR angiography were both normal. Following cessation of escitalopram, heart rate was 50-60 bpm.
Patient 2:
A 70-year-old female patient was admitted to the outpatient clinic with depressive symptoms and was diagnosed with major depression. She had no history of any treatment with antidepressants or other medications. After administration of 5 mg/day escitalopram, the patient's blood pressure and pulse rate were mildly reduced, and she had daily presyncopal episodes. After 1 week of treatment, the dose of escitalopram was increased to 10 mg/day, and the patient complained about dizziness. In this case, we found that presyncopal episodes lasted longer and that both hypotension and bradycardia increased. The ECG described a normal sinus rhythm, but heart rate was 30-40 bpm. These symptoms disappeared within 24 hours after escitalopram treatment was d i s c o n t i nu e d . T h e p a t i e n t p r e s e n t e d a incidentally discovered severe asymptomatic sinus bradycardia with a heart rate of 45 bpm, and her blood pressure was stable at 120/70 mmHg. Escitalopram was stopped immediately. Within 24 hours, the ECG revealed a regular sinus rhythm with a heart rate of 60 bpm. During follow-up, no complications were observed, and the sinus cardiac rhythm was maintained. Cardiac evaluation revealed a slightly dilated cardiomyopathy, more noticeable in the left ventricle. The depressive state was later treated with 150 mg a day venlafaxine, a specific inhibitor of serotonin and noradrenaline uptake, without any further occurrence of bradycardia and with a good clinical response.
Patient 3:
A 75-year-old female patient arrived at our outpatient clinic with symptoms of mild memory impairment, crying, and depressive symptoms. The patient, a retired teacher, had no known diseases or chronic use of medicine. She scored 19 on the Beck Depression Inventory, 24 points on the Mini-Mental State Exam and 21 points on the Montreal Cognitive Assessment. Escitalopram treatment, 5 mg/day, was started for depression and mild cognitive impairment, but this caused a heart rate of about 40 bpm during the first week. As a result, treatment was continued with venlafaxine.
DISCUSSION
We report on three elderly individuals experiencing sinus bradycardia after escitalopram treatment; the sinus bradycardia resolved after the discontinuation of escitalopram.
There is limited information on the risk of QT prolongation and cardiac arrhythmias with escitalopram. Previous studies have shown that QT prolongation and torsades de pointes are associated with citalopram overdose [10] [11] [12] [13] , but it is unclear whether escitalopram has a similar association with QT prolongation. Three cases of QT prolongation with escitalopram overdose are presented [4] [5] [6] , and a retrospective review of escitalopram overdoses from a regional poison center revealed ECG changes. However, specific ECG abnormalities were not reported 8 . No animal studies on the effect of the citalopram enantiomers on the QT interval have been reported, making it difficult to determine whether the QT abnormalities seen with citalopram are due to the S-enantiomer, R-enantiomer, or both. It is therefore important to confirm that escitalopram poisoning causes QT prolongation in a larger series of cases and estimate the frequency of abnormal QT intervals.
Elderly patients have a higher exposure to both citalopram and escitalopram due to age-related declines in metabolism and elimination. The maximum dose of both medicines has thus been restricted in patients older than 65 years 14 . We also speculate that the initiation of antidepressants inhibiting CYP2D6 would be associated with an increased risk of bradycardia-related symptoms and hospital visits among elderly patients. Atherosclerosis and coronary and cerebrovascular diseases are frequently observed in elderly individuals, which is why bradycardia may present in asymptomatic patients who are treated with an SSRI. As elderly individuals with anxiety and those whose heart rate is about 50-60 bpm are treated with SSRIs, their levels of anxiety decrease. Along with this response, their heart rates, which are already at the lower limit, also decrease, which can produce bradycardia. The issue of whether comorbid cerebrovascular or cardiovascular disorders should be a consideration in the choice of antidepressants remains to be clarified. Nevertheless, these cases provide anecdotal evidence that caution is warranted when using citalopram/escitalopram to treat patients prone to cardiovascular side effects due to SSRI use.
In conclusion, this case series report suggests that escitalopram may induce bradycardia in some elderly patients. Although this type of bradycardia produces no clinical consequences in most patients, thereby allowing classification of escitalopram as safe, it produces serious consequences in some cases. Clinicians should be aware of this possibility and perform clinical monitoring of heart rate, ECG, and blood pressure when escitalopram treatment is introduced, particularly in elderly patients with suspected or known underlying heart disease. Another SSRI or noradrenergic medicine should b e c h o s e n f o r p a t i e n t s w i t h p r e v i o u s bradycardias whose heart rates are normally 50-60 bpm.
